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LETTERS TO THE EDITORRegarding “Serum total 8-iso-prostaglandin F2: A
new and independent predictor of peripheral arterial
disease”
We read with great interest the important paper by Mueller et
al1 who demonstrated that serum 8-iso-prostaglandin F2 is an
independent risk factor for peripheral arterial disease. We would
like to convey some of our own findings, which may be of mech-
anistic and therapeutic relevance.
First, we demonstrated that 8-isoprostane F2 up-regulates
nicotinamide adenine dinucleotide phosphate (NADPH) oxi-
dase expression in vascular tissue and as such, promotes the
formation of superoxide.2 Superoxide elicits a number of vascu-
lopathic effects, including the inhibition of nitric oxide (NO)
bioavailability, endothelial cell apoptosis, and lipid peroxida-
tion.3 Since these are all components of peripheral arterial
disease, the potential for NADPH oxidase to promote vascu-
lopathy is clear. In turn, since superoxide itself promotes the
formation of 8-isoprostane F2, a self-perpetuating cycle may
ensue that results in the further generation of oxidative stress.2
In a more recent study, we found that superoxide itself pro-
motes NADPH oxidase expression, further augmenting this
cycle.4
These oxidative reactions also result in a reduction of endog-
enous vascular prostacyclin (PGI2) formation.
2 PGI2 is vasculopro-
tective in that it counters the actions of 8-isoprostane F2, in
particular, the inhibition of platelet and leukocyte activity and
adhesion.2 In this context, we found that the PGI2 analogue,
iloprost, is a potent inhibitor NADPH oxidase up-regulation elic-
ited by 8-isoprostane F2.
2 These data therefore indicate that
NADPH oxidase upregulation results in an imbalance between
8-isoprostane F2 and PGI2 that would favor intravascular oxida-
tive stress and vasculopathy.
In contrast, we found that aspirin had no effect on NADPH
oxidase expression.5 Because 8-isoprostane F2 is formed by
an oxidative pathway and not by cyclooxygenase,1,2 aspirin
may have little effect on 8-isoprostane F2 formation. This
may explain, in part, why aspirin is not optimally effective in
treating peripheral vascular disease or the clinical complica-
tions associated with the condition.6 However, we found that
NO-donating aspirins were potent inhibitors of NADPH oxi-
dase expression, an effect mediated by the NO moiety of the
drug.5
In more recent studies, we also found that homocysteine
augments the formation of 8-isoprostane F2 in arteries from
experimental diabetic models through an NADPH oxidase-super-
oxide mediated mechanism (Jeremy, unpublished observations).
Since homocysteine and diabetes mellitus are both risk factors for
peripheral vascular disease, this further consolidates the potentially
key role played by oxidative stress and 8-isoprostane F2 in the
etiology of peripheral arterial disease.
From a therapeutic perspective, it would be expected that
thromboxane A2 (TXA2) receptor antagonists may be useful in
treating peripheral vascular disease, because 8-isoprostane F2
activates the TXA2 receptor.
1,2 One possible problem is that
factors other than 8-isoprostane F2, including angiotensin II,
cytokines and hypoxia, upregulate NAPDH oxidase. However,
treatment with a TXA2 antagonist could be augmented by the
co-administration of iloprost (or an oral equivalent, such as
beraprost) in combination with NO-aspirin, an NADPH oxi-
dase inhibitor, or both. Such possibilities warrant further con-
sideration.Jaime Y. Jeremy, PhD
Saima Muzaffar, PhD
Gianni D. Angelini, PhD
Nilima Shukla, PhD
Bristol Heart Institute
University of Bristol
Bristol, United Kingdom
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Reply
We thank Dr Jeremy and colleagues for their kind interest in
our recent article demonstrating that increased oxidative stress, as
measured by 8-iso-prostaglandin F2, may be associated with
peripheral arterial disease. In this context, we appreciate the results
of the mechanistic experiments by Dr Jeremy and colleagues
summarized in their letter to the editor.
Considering the proposed therapeutic implications of in-
creased oxidative stress in peripheral arterial disease, Dr Jeremy and
colleagues mainly refer to prostacyclin analogues, nitric oxide-
donating nonsteroidal antiinflammatory drugs, and thromboxane
A2 receptor antagonists. However, although superoxide dismutase
mimetics, thiols, xanthine oxidase, and nicotinamide adenine dinu-
cleotide phosphate (NADPH) oxidase inhibitors are currently
receiving much interest in developing strategies to reduce oxida-
tive stress in atherosclerosis, we would like to point out the
evidence that drugs in common clinical use, like 3-hydroxy-3-
methylglutaryl coenzymeA (HMG-CoA) reductase inhibitors (sta-
tins), angiotensin-converting enzyme (ACE) inhibitors, and an-
giotensin II type 1 (AT1)- receptor blockers may also lower
oxidative stress.
A number of clinical trials have shown that statins improve
endothelial dysfunction in patients with coronary risk factors be-
yond what could be attributed to their impact on plasma lipids.1
The pleiotropic effects of statins include improvement of endothe-
lial dysfunction, increased nitric oxide bioavailability, antioxidant
properties, inhibition of inflammatory responses, and stabilization
of atherosclerotic plaques.2,3 ACE inhibitors and AT1-receptor
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